| ACh | Acetylcholine |
| AChE | Acetylcholinesterase |
| eeAChE | eel AChE |
| hAChE | human AChE |
| AChEI | Acetylcholinesterase inhibitor |
| AD | Alzheimer’s disease |
| Aβ | Amyloid-β |
| BACE1 | β-site APP cleaving enzyme-1 |
| BBB | Blood-brain-barrier |
| BHT | Butylated hydroxytoluene |
| BuChE | Butyrylcholinesterase |
| eqBuChE | equine serum BuChE |
| CAS | Catalytic active (or anionic) site |
| ChAT | Choline acetyltransferase |
| ChE | Cholinesterase |
| CINs | Cholinergic interneurons |
| CuAAC | Cu(I))-catalyzed alkyne–azide 1,3-dipolar cycloaddition |
| DIPEA | N,N-Diisopropylethylamine or Hunig’s base |
| DMF | Dimethylformamide |
| DMSO | Dimethylsulfoxide |
| 5HT3 | 5—hydroxy tryptamine (Serotonin)- receptor-3 |
| LDH | Lactate dehydrogenase |
| LOX | Lipoxygenase |
| MAO | Monoamine oxidase |
| MG | Myasthenia gravis |
| MTDL | Multi-target-directed-ligand |
| NDs | Neurodegenerative disease |
| NFT | Neurofibrillary tangles |
| NMJ | Neuromuscular junction |
| NO | Nitric oxide |
| NT | Neurotransmitter |
| PAS | Peripheral anionic site |
| PD | Parkinson’s disease |
| ROS | Reactive oxygen species |
| SAR | Structure activity relationship |
| TBPB | tert-butyl peroxybenzoate |
| THF | Tetrahydrofuran |